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Neural transplantation is a promising therapeutic strategy for neurodegenerative diseases
and other disorders of the central nervous system (CNS) such as Parkinson and Hunting-
ton diseases, multiple sclerosis or stroke. Although cell replacement therapy already went
through clinical trials for some of these diseases using fetal human neuroblasts, several
signiﬁcant limitations led to the search for alternative cell sources that would be more suit-
able for intracerebral transplantation.Taking into account logistical and ethical issues linked
to the use of tissue derived from human fetuses, and the immunologically special status of
the CNS allowing the occurrence of deleterious immune reactions, neural stem/progenitor
cells (NSPCs) appear to be an interesting cell source candidate. In addition to their ability for
replacing cell populations lost during the pathological events, NSPCs also display surprising
therapeutic effects of neuroprotection and immunomodulation. A better knowledge of the
mechanisms involved in these speciﬁc characteristics will hopefully lead in the future to a
successful use of NSPCs in regenerative medicine for CNS disorders.
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THE CENTRAL NERVOUS SYSTEM, AN ORGAN WITH AN
“IMMUNOLOGICALLY SPECIAL” STATUS
Inﬂammation is the primary response of the immune system
that occurs to defend the organism against danger signals pro-
voked by an infection or irritation consecutive to the intrusion
of pathogens. The speciﬁc property of the immune system is
to discriminate the self from the non-self and thus to identify
and eliminate the infectious agents. From this same mechanism
originates the phenomenon of rejection in transplantation. How-
ever, since Van Dooremal work in 1873 on tumor cell graft in
the eye anterior chamber, it is known that speciﬁc sites in the
organism display limited immune reactions. In 1948, Sir Peter
Medawar, Nobel Prize of Medicine and pioneer in the ﬁeld of the
immunology of transplantation, proposed the term of “immune
privilege” to describe a reduced inﬂammation after inoculation of
allogeneic tissues in some organs like the brain or the eye anterior
chamber (Medawar, 1948). Later, this deﬁnition was extended to
the particular property of speciﬁc organs or tissues to display a
prolonged, and sometimes inﬁnite, survival when grafted in con-
ventional sites of the organism. Thus, throughout the years, the
cornea, the placenta, the eye anterior chamber (Billingham and
Boswell, 1953; Hori et al., 2000), or the testis (Head et al., 1983)
were examples of well-studied immune-privileged tissues. In this
context, the central nervous system (CNS) and the immune system
were traditionally perceived as separate morphological and func-
tional entities, preventing the disturbance of the CNS homeostasis
which is crucial to neuronal functioning. This vision that the CNS
could escape the immune surveillance was supported by the dis-
covery of the blood–brain barrier (BBB) preventing the exchange
between a wide range of soluble molecules from the blood and
the brain, like growth factors, cytokines, or immunoglobulins
(Goldstein and Betz, 1983; Joó, 1993). In addition, there is no
proof of the existence of professional antigen presenting cells like
dendritic cells, B cells, and macrophages in the unlesioned CNS
(Wekerle et al., 1987) preventing the initiation and propagation of
antigen-speciﬁc immune responses in the brain. In physiological
conditions, the expression of antigens from the major histocom-
patibility complex (MHC) by neural cells is very weak and even
in some cases undetectable (Barker and Billingham, 1977; Mauer-
hoff et al., 1988) allowing these cells to escape the recognition by
antigen-speciﬁc T cells. However, only the normal CNS displays
such an absence of immune response.
During certain pathological processes, speciﬁc genes are acti-
vated leading to the change of this immunologically non-reactive
tissue into an environment favorable to the development of
inﬂammatory reactions. In these conditions, macrophages are
recruited from the pool of blood monocytes and inﬁltrate the
perivascular spaces. In addition, microglial cells from the CNS
are activated and acquire phagocytosis and antigen presentation
abilities (Aloisi, 2001). Microglia can induce the production of
pro-inﬂammatory cytokines like TNF and IL-1β (Sivakumar et al.,
2011) and, along with reactive astrocytes, become able to present
antigens through class I and II MHC molecules (Höftberger et al.,
2004), allowing CNS-inﬁltrated T cells to recognize the antigenic
peptides and behave as potent immune effectors (Cornet et al.,
2000). The last two decades have thus witnessed the questioning
of the concept of immune privilege. Discovery of the perme-
ability of the BBB under pathological circumstances (Kebir et al.,
2007), the existence of an unconventional lymphatic drainage in
the CNS (Hatterer et al., 2006), and the migration of leucocytes
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across the BBB on a regular basis (Hickey et al., 1991; Cayrol et al.,
2008) were convincing proofs of the strong bidirectional com-
munication between the immune and the nervous systems. The
brain is now more readily considered as an organ with special
immune characteristics and subject to immunological surveil-
lance than a strictly immune-privileged tissue (Hickey, 2001). This
dual status of the CNS, being both more favorable to the trans-
plantation than the periphery but also a propitious environment
for deleterious inﬂammatory reactions in response to pathologi-
cal conditions (Kerschensteiner et al., 2009) could in part explain
why fetal neuron allografts in the brain are usually well tolerated
under moderate immunosuppressive treatment (Björklund and
Lindvall, 2000; Bachoud-Lévi et al., 2006; Krystkowiak et al., 2007)
while intracerebral xenografts are systematically rejected (Larsson
et al., 2000).
CELL REPLACEMENT THERAPY FOR THE CNS
Neuronal cell death is the main characteristic of CNS acute disor-
ders like stroke or trauma but also of neurodegenerative diseases
including Alzheimer, Parkinson, and Huntington diseases. As
the adult CNS displays very weak capacities of endogenous cell
replacement and repair, both being necessary to attain a signiﬁcant
functional recovery, cell replacement therapy for the CNS repre-
sents a promising avenue for the treatment of these pathological
conditions. In fact, clinical impact of cell replacement strategy
has already been assessed in Parkinson disease patients by allo-
transplantation of fetal mesencephalic cells. The results of the
clinical trials showed, in some patients, a long-term symptomatic
improvement associated with a survival of the grafted cells and
a partial reinnervation of the striatum (Björklund and Lindvall,
2000). A functional recovery has also been noticed in a small
cohort of patients suffering from Huntington disease and grafted
with human fetal striatal neuroblasts (Bachoud-Lévi et al., 2000,
2006), with one study even showing integration of cells from the
donor into the host tissue (Freeman et al., 2000). Despite these
promising outcomes, several issues remain to be assessed (Björk-
lund et al., 2003). Tissue availability, ethical and logistical concerns
linked to the use of human material, cell viability and purity,
or appearance of deleterious side-effects like dyskinesia (Olanow
et al., 2003) represent important obstacles that need to be over-
come before resuming clinical trials on neural allotransplantation.
Moreover, the discovery of biological signs of alloimmunization
to donor’s antigens like the appearance of anti-HLA antibodies
in Huntington disease patients following fetal neural grafts (Krys-
tkowiak et al., 2007) underlined the importance of considering
immune responses in the CNS as a crucial parameter for future
cell transplantation strategies. In order to at least circumvent some
of the problems mentioned above, alternative cell sources for
intracerebral transplantation like porcine neuroblasts have been
considered (Pakzaban and Isacson, 1994).
INTRACEREBRAL XENOTRANSPLANTATION
Porcine fetal neural tissue has been for a long time considered
as the more adequate cell source for xenotransplantation in the
human brain. Indeed, swine offer the advantage of a relatively
easy breeding allowing an excellent access to fetal material and
can be genetically modiﬁed. In fact, porcine fetal cells have been
proven to be an efﬁcient source for cell therapy in animalmodels of
neurodegenerative diseases. Interest in these cells started to grow
after ﬁrst studies revealed that xenografts derived from the ventral
mesencephalon of pigs (21–26 days of gestation) could survive in
the brain of a rat model of Parkinson disease under immunosup-
pression (Freeman et al., 1988; Huffaker et al., 1989). Beyond the
long-term survival, xenotransplanted neural cells also displayed
a long-distance axonal outgrowth (Wictorin et al., 1990; Deacon
et al., 1994). Isacson et al. (1995) have shown that neurons iso-
lated from several areas of the porcine fetal brain and transplanted
in homotypic or ectopic lesioned cerebral regions of an adult
rat could project axons in the deafferented zones, thus rebuild-
ing the brain parenchyma cytoarchitecture. This inter-species and
targeted axonal growth of porcine dopaminergic neuroblasts sig-
niﬁcantly restored in several months an efﬁcient dopaminergic
innervation. A signiﬁcant functional recovery in transplanted rats
was also observed and was correlated to the number of tyrosine
hydroxylase (TH)-positive cells and to the size of the graft (Galpern
et al., 1996). Encouraging results obtained from animal models of
Parkinson disease led to small-scale clinical trials. Isacson’s group
performed a study where 12 Parkinson disease patients received
a unilateral striatal graft constituted of a porcine ventral mesen-
cephalon (25–28 days of gestation) cell suspension (Schumacher
et al., 2000). Even though a signiﬁcant decrease in Uniﬁed Parkin-
son’s Disease Rating Scale (UPDRS) scores was observed, positron
emission tomography (PET) analyses did not show any increase
in the [18F]ﬂuorodopa uptake, underlining a lack of improve-
ment in axon termination density of dopaminergic neurons from
the graft and no increase in dopa-decarboxylase activity. More-
over, a postmortem study revealed that only 638 TH-positive cells
out of the 12 millions of porcine neuroblasts transplanted had
survived at that stage, with a lymphocytic inﬁltration at the bor-
der and within the graft, despite the fact that the patient was
under cyclosporine A treatment (Deacon et al., 1997). If some
work has shown that neural xenografts are able to survive for
a long time in the CNS without the use of immunosuppressors
(Björklund et al., 1982; Daniloff et al., 1985), most of the recent
studies, including those from our group, indicate that intracere-
bral xenografts trigger a strong immune reaction leading to the
fast destruction of the graft through the invasion of microglial
cells/macrophages, T lymphocytes, and dendritic cells within 5–
7 weeks post-transplantation (Rémy et al., 2001; Melchior et al.,
2002; Michel et al., 2006; Figure 1). Xenograft rejection is more
aggressive than that observed with allotransplantation and mainly
occurs through the involvement of T cells. A genetically modi-
ﬁed swine has been engineered to express CTLA4-Ig, a human
molecule inhibiting T cells, under the neuron-speciﬁc enolase pro-
moter. This construction allowed porcine transgenic neurons to
locally deliver an immunosuppressive molecule after transplan-
tation in the brain (Martin et al., 2005). In the CNS, xenograft
survival has been signiﬁcantly prolonged by administration of
immunosuppressive drugs targeting T cells like cyclosporine A.
However, this immunosuppressor at doses required to inhibit the
rejection process has strong sides effects (Rezzani, 2006) and is
only transiently efﬁcient. Graft rejection has also been delayed
when the T cell receptor (TCR) and the IL-2 receptor α chain
(CD25) were inactivated, and in the case of CD4-positive T cell
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depletion (Honey et al., 1990; Okura et al., 1997). The admin-
istration of two successive high doses of anti-CD4 monoclonal
antibodies resulted in a longer survival of discordant xenografts
(between species differing from the expression of the gal epitope,
like pig and human), although not prolonged, suggesting that
other immune components than T cells are implicated (Wood
et al., 1996). Indeed, B cells and immunoglobulins have been
shown to intervene in the survival and function of the graft. The
importance of immunoglobulins has been highlighted by compar-
ing the survival of a cell suspension derived from porcine ventral
mesencephalon xenografted in the brain of wild-type (WT) or
immunoglobulin-deﬁcient (Ig-KO) mice. Most of the Ig-KO mice
displayed for more than 4 weeks a functional graft with very little
immune cell inﬁltration while xenograft survival beyond 4 days
remained exceptional in WT mice. After a prolonged survival of
about 4 weeks, an immune cellular response with a high pro-
portion of CD8-positive T cells occurred and led to the rejection
of the graft in Ig-KO mice (Larsson et al., 1999). These observa-
tions indicate that immunoglobulins play an important part in
the fast initiation of discordant neural xenografts rejection, a phe-
nomenon that appears to be unavoidable despite all the efforts
made to control it. Overall, these pre-clinical and clinical stud-
ies led to disappointing results and limited the enthusiasm and
hope initially raised by the use of fetal xenogeneic neuroblasts in
regenerative medicine. It is now important to ﬁnd more adequate
cell sources for intracerebral transplantation. In theory, the ideal
candidate should be tolerogenic and safe and have the proper-
ties to be easily ampliﬁed, resist to long-term storage, be efﬁcient
for cell replacement and allow manipulation to adjust to a spe-
ciﬁc pathology. Until these days, no cell type possesses all those
characteristics and several cells at different stages of the neuronal
lineage have been tested in animal models and clinical trials (Guil-
laume and Zhang, 2008). Among them, neural stem/progenitor
cells (NSPCs) seem to represent a good candidate.
NSPCs, THE FUTURE OF INTRACEREBRAL
TRANSPLANTATION?
Stem cells are deﬁned by their ability to self renew to maintain
the pool of undifferentiated cells, to proliferate to give rise to
lineage-restricted progenitors, and to differentiate into a range of
mature cell types. Among them, multipotent neural stem cells
(NSCs), derived from embryonic or adult nervous systems, can
be cultivated in vitro as neurospheres, a mixture of neural stem
cells and progenitors (NSPCs), in presence of growth factors
such as bFGF (Vescovi et al., 1993; Gritti et al., 1996), and EGF
(Reynolds andWeiss, 1992). Withdrawal of growth factors induces
their differentiation into neurons, astrocytes, and oligodendro-
cytes (Reynolds and Weiss, 1992; Reynolds et al., 1992). These
properties make them an interesting source of cells for neural
repair after injury or disease. Besides their differentiation poten-
tial, NSPCs seem to have a selective advantage for their survival
when transplanted in the brain. In a xenotransplantation context,
Armstrong and colleagues as well as our group demonstrated that
porcine NSPCs were able to survive longer than porcine neurob-
lasts when grafted into the striatum of non-immunosuppressed
rats (Armstrong et al., 2001; Michel-Monigadon et al., 2011). As
NSPCswere reported to express noor low levels of MHCmolecules
FIGURE 1 | Characterization of xenograft infiltration by activated
immune cells. Kinetics (A). In the absence of immunosuppressive
treatment, the rejection process of fetal neurons xenografted in the rat
striatum involves cells from the macrophagic lineage. After a peak of
microglial activation and dendritic cell inﬁltration in the ﬁrst days
post-transplantation, probably consecutive to the surgery, a latency phase
is observed. Around 5 weeks post-transplantation, rejection process is
initiated and strong microglial cell activation at the border but also within
the graft is observed. This phenomenon is strongly correlated with a
massive T cell and dendritic cell inﬁltration. Immunostaining (B). Speciﬁc
porcine neuroﬁlament is revealed by NF70 antibody and allows visualization
of the graft. Immune reaction is assessed by Ox62 (dendritic cells), Ox42
(microglial cells/macrophages), and R73 (T cells) antibodies. Scale bar:
200 μm.
(Klassen et al., 2001; Hori et al., 2003), this phenomenon was
ﬁrstly linked to a lesser immunogenicity of these cells compared
to more mature cells (Odeberg et al., 2005). However, immuno-
genic properties of NSPCs cannot totally justify their delayed
rejection, and recent studies conﬁrmed the expression of MHC
class I and class II molecules by NSPCs, under normal or inﬂam-
matory conditions (Sergent-Tanguy et al., 2006; Johansson et al.,
2008; Yin et al., 2008; Laguna Goya et al., 2011). Beneﬁcial effects
of NSPC transplantation have been shown in pre-clinical mod-
els of several neurologic disorders such as Parkinson disease
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(Richardson et al., 2005), Huntington disease (McBride et al.,
2004), or multiple sclerosis but also in other pathologies includ-
ing renal ischemia-reperfusion (Wang et al., 2009b). However, the
different mechanisms by which these cells exert their therapeutic
effect remain unclear. The replacement of cells that have been lost
or damaged was for a long time thought to be the main function
of transplanted stem cells but it is now clear that somatic stem
cells could also induce several beneﬁcial effects far beyond the
cell replacement itself. For instance, it has recently been demon-
strated that several stem cell types (embryonic, mesenchymal, or
neural) display a strong immunosuppressive potential (Fändrich
et al., 2002; Zappia et al., 2005; Einstein et al., 2007), favorable
to their use in transplantation strategies for immune-related dis-
eases like multiple sclerosis. It is also possible that NSPCs induce
neural repair through intrinsic properties of neuroprotection and
immunomodulation by releasing directly at the graft site a range of
molecules (immunomodulatory molecules, growth factors, stem
cell regulatory factors) spatially and temporally orchestrated by
the microenvironment (Pluchino et al., 2009).
ADMINISTRATION ROUTE AND SOURCE OF
TRANSPLANTED NSPCs
Deﬁning the best route of administration of cells represents a con-
straint for NSPC transplantation and is very dependent on the
type of CNS lesions (focal or multifocal). Anatomic and patho-
logic characteristics of CNS focal disorders like Parkinson disease,
spinal cord lesions, Huntington disease, or stroke suggest that
intracerebral transplantationof cells directly at the site of the lesion
would be the more appropriate strategy to facilitate tissue regener-
ation. However, the presence of several lesion areas in diseases like
multiple sclerosis or epilepsy represents a major limit for intrale-
sional cellular transplantation approaches, and some groups were
able to show a therapeutic effect of NSPC systemic transplan-
tation by intravenous or intrathecal route (Pluchino et al., 2003;
Einstein et al., 2007). Efﬁciency of restorative transplantation can
also depend on the differentiation stage of the grafted cells. In
some cases where a speciﬁc cell type is selectively lost during the
pathogenic event, like the dopaminergic neurons in Parkinson
disease, transplantation of pre-differentiated cells sharing similar
properties in the affected region could allow a better functional
recovery (Kim et al., 2002; Lévesque et al., 2009). However, the
use of multipotent undifferentiated cells could be the best strat-
egy in the case of a lesion or disease affecting several cell types
in extended areas. Indeed these cells could spontaneously dif-
ferentiate in vivo under the inﬂuence of the microenvironment
in cells with desired phenotypes. It has recently been show that
undifferentiated human NSPCs could survive and differentiate
into neurons and glial cells after xenotransplantation into the rat
spinal cord (Mothe et al., 2011).
AUTO, ALLO, AND XENOTRANSPLANTATION OF NSPCs
Autologous NSPCs derived from rodent adult nervous tissue and
transplanted in the CNS can functionally integrate in the cerebral
parenchyma, conﬁrming their potential use in therapy (Taupin
and Gage, 2002). Isolation of NSPCs from the human adult
brain offers the opportunity to perform autologous transplan-
tation, in which NSPCs would be isolated from an unlesioned
region of the CNS, ampliﬁed in culture and reimplanted in the
patient to repair cerebral or spinal damage without the need for
immunosuppressive treatment (Pfeifer et al., 2006). To date, autol-
ogous transplantation of differentiated NSPCs was performed in
one Parkinson disease patient with encouraging results (Lévesque
et al., 2009). If the invasive surgery to isolate NSPCs may have
critical consequences like permanent damage in the taking area,
this strategy presents the advantage to avoid immune compatibil-
ity problems and could allow patient-speciﬁc gene modiﬁcations
of the cells prior to transplantation (Stojkovic and Lako, 2011).
Genetic engineering of autologous NSPCs could for example be
used to repair potential genetic damage linked to the patient’s
disease (like in Huntington disease), stimulate dopaminergic dif-
ferentiation in the case of Parkinson disease (Wagner et al., 1999)
or dedifferentiate NSPCs toward a pluripotent state using the Oct4
gene (Kim et al., 2009). Despite the immunologically special status
of theCNS, long-term survival of neural allografts is compromised
in the host without immunosuppression (Krystkowiak et al., 2007;
Rota Nodari et al., 2010). Immunogenicity is therefore an impor-
tant parameter to consider for the survival of transplanted cells.
NSPCs express class I MHC and co-stimulatory molecules (Imi-
tola et al., 2004; Sergent-Tanguy et al., 2006) but the expression
of MHC class II molecules remain undetectable in physiological
conditions (Hori et al., 2003). However in the case of an inﬂamma-
tory process, in particular under IFNγ exposure, the expression of
immunogenic molecules at NSPC’s surface is strongly increased
(Johansson et al., 2008; Laguna Goya et al., 2011) which com-
promises their survival and consequently their long-term effects.
Moreover, NSPC allotransplantation studies have revealed that
NSPCs derived from adult tissue could be less efﬁcient than those
derived from the fetal CNS (Guillaume and Zhang, 2008). Indeed,
the latter have demonstrated a greater capacity of proliferation
in vitro and would more easily differentiate into neurons in vivo.
NSPCs derived from the adult brain display weak propensity to
integrate in the cerebral tissue, show limited synapse formation
and their survival remains relatively short (Dziewczapolski et al.,
2003), compromising a potential functional recovery. These obser-
vations suggest that NSPCs should preferentially be isolated from
the fetal CNS prior to transplantation. However, one must keep
in mind that the use of human fetal NSPCs, like ES cells, is lim-
ited by ethical and logistical issues. The use of NSPCs from animal
species like swine could alleviate problems linked to the use of fetal
human cells. In several studies, porcineNSPCs have been shown to
have a reduced immunogenicity that could optimize their survival
in vivo (Armstrong et al., 2001). Porcine NSPCs are also particu-
larly interesting because of their multipotency. Barker’s group has
demonstrated that porcine NSPCs xenografted in cyclosporine A-
immunosuppressed rats presenting a 6-hydroxydopamine lesion
to model Parkinson disease could differentiate into dopaminer-
gic neurons (Armstrong et al., 2002). In addition, the xenografted
cells have proven to signiﬁcantly integrate in the host tissue and
partially reconstitute damaged neuronal circuitry (Harrower et al.,
2006). In a recent study, our group has shown that NSPCs derived
from the cerebral cortex of pig embryos at 28 days of gestation
could survive signiﬁcantly longer than porcine neuroblasts iso-
lated from the ventral mesencephalon after transplantation in the
brain of non-immunosuppressed rats. This prolonged survival
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was associated with an absence of T lymphocyte, dendritic and
activated microglial cell inﬁltration within the NSPC healthy
grafts and with a trophic effect of the grafted cells on the host
dopaminergic system (Michel-Monigadon et al., 2011). However,
we did not observe any dopaminergic differentiation suggesting
that NSPCs could be beneﬁcial far beyond the cell replacement
process itself.
THERAPEUTIC EFFECTS OF TRANSPLANTED NSPCs
CELL REPLACEMENT
Human NSPCs transplanted in the brain of immunodeﬁcient
mice can proliferate, migrate, and differentiate depending on
the injection site (Tamaki et al., 2002). Allotransplantation of
NSPCs has proven to be efﬁcient in animal models of stroke
and spinal cord lesion. Murine NSPCs from C17.2 cell line
implanted in an ischemic mouse brain could survive, integrate,
and differentiate into neurons and glial cells (Snyder et al., 1997).
Animal models of cerebral ischemia have also been used to
demonstrate that NSPCs delivered by intraventricular injection
could migrate toward and through the damaged tissue, inte-
grate, and differentiate into the main neural cell types (Riess
et al., 2002). Moreover, NSPCs genetically modiﬁed to overex-
press NT-3 have shown a potent integration and a signiﬁcant
regenerative capacity in a model of hypoxic and ischemic cere-
bral lesion, associated with a decrease in the severity of brain
parenchyma damage, an improvement of axonal outgrowth, and
a diminution of the glial scar (Park et al., 2006). These studies
suggest that, under certain conditions, the lesioned CNS could
represent a permissive environment for the maintenance of trans-
planted NSPCs. Functional integration and reconstruction of the
neuronal circuitry is an important goal for restorative therapy. In
this context, several groups have shown that NSPCs cultured in
vitro could give rise to functional neurons connected and elec-
trically active (Auerbach et al., 2000) that could integrate in the
host cortical connections after transplantation (Snyder et al., 1997;
Lundberg et al., 2002; Park et al., 2002). Despite these encourag-
ing results, proofs of the ability of NSPCs to differentiate into
a sufﬁcient number of functional neurons that could regener-
ate lost functions by massive cell replacement remain relatively
rare. Functional beneﬁts resulting from NSPC transplantation
are hardly correlated to the number of fully differentiated neu-
ral cells obtained from the grafted cells. This inefﬁciency to
complete the differentiation process and the tendency to main-
tain an undifferentiated phenotype within the host tissue suggest
that transplanted NSPCs partially exert their therapeutic effect by
alternative mechanisms.
NEUROPROTECTION
Transplanted NSPCs can signiﬁcantly improve the survival and
the functions of endogenous glial and neuronal progenitor cells
that have survived the pathologic event. NSPCs display a strong
tropism for tissue lesions and seem to migrate toward these
critical sites to release molecules preventing death and facilitat-
ing regeneration of targeted cell populations (Ourednik et al.,
2002). Several groups are interested in this particular tropism
of NSPCs and stem cells in general for damaged zones. This
property could indeed be used to deliver therapeutic molecules
directly in the lesioned area using genetically engineered stem
cells (Müller et al., 2006). This type of strategy would especially
be appropriate in ischemic pathologies where altered blood ﬂow
decreases the access to the lesion site by systemic administration
route. NSPC’s neuroprotective effect often goes along with an
increase in the bioavailability of the main neurotrophic factors
like NGF, BDNF, CNTF, and GDNF (Carletti et al., 2011). This
has been demonstrated in rodents suffering from primary cen-
tral inﬂammatory diseases like multiple sclerosis (Pluchino et al.,
2003), spinal cord lesions (Lu et al., 2003), or stroke, and also
in rodent models of neurodegenerative disorders associated with
an immune reaction such as Parkinson and Huntington diseases
(McBride et al., 2004; Ryu et al., 2004; Richardson et al., 2005). Cel-
lular and molecular mechanisms implicated in this phenomenon
remain unclear but may reside in the intrinsic properties of neu-
rospheres, cellular artifacts resulting from NSPC culture and from
which most of transplanted NSPCs are derived. Typically, neu-
rospheres are generated in vitro after about 10 days in culture
in the absence of serum and in the presence of high concen-
trations of growth factors (EGF/bFGF). This culture protocol
allows the selection of NSPCs responding to those factors. Thus,
after transplantation, neurosphere-derived NSPCs might be more
sensitive to environmental signals (especially bFGF) in the host
tissue triggering neurotrophin secretion by neighboring cells (Lu
et al., 2003).
IMMUNOMODULATION
Accumulating evidence suggest that stem cells, like mesenchymal
stem cells (MSCs) or embryonic stem cells, could interact with
components of the immune system, leading to the modulation
of many effector functions (Fändrich et al., 2002; Zappia et al.,
2005). For instance, MSCs are known to suppress T cell prolif-
eration in vitro (Di Nicola et al., 2002) and to induce long-term
graft survival in an allogeneic context (Bartholomew et al., 2002;
Chabannes et al., 2007). Regarding NSPCs, a growing number of
studies highlighted their immunomodulatory properties, in vivo
and in vitro (Bonnamain et al., 2011). It was clearly demonstrated
that NSPCs were able to attenuate experimental autoimmune
encephalomyelitis (EAE) when injected centrally or peripherally
(Einstein et al., 2003, 2007; Pluchino et al., 2005). If the site of
action (i.e., CNS or lymph nodes) is not clearly deﬁned, NSPCs
have the capacity to inhibit the proliferation of lymph nodes-
derived T cells, in response to either concanavalin A (ConA) or
to myelin oligodendrocyte glycoprotein, in vitro (Einstein et al.,
2003). A recent study showed that syngenic NSPCs transplanted
in a model of focal spinal cord injury were able to interact
with activated-macrophages in situ to decrease their number and
increase the proportion of regulatory T cells (Cusimano et al.,
2012). This conﬁrms the importance of the interactions between
NSPCs and immune cells to reconﬁgure the deleterious inﬂamma-
tory environment and thus promote the healing or regeneration
processes. As systemic transplantation of NSPCs was shown to
be beneﬁcial in animal models of autoimmune disease like mul-
tiple sclerosis (Einstein et al., 2007), it could be hypothesized that
NSPCs exert their immunomodulatory effect through a strong
paracrine mechanism. Previous studies revealed the expression of
immune molecules like TGFβ-1 by NSPCs (Klassen et al., 2003),
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or inducible nitric oxide synthase (iNOS) and prostaglandin E2 in
NSPC cell line (Wang et al., 2009a). Even if the implication of some
of these molecules in the immunosuppressive effect of NSPC cell
line has already been suggested, the mechanism remains poorly
understood.
CONCLUSION
Signiﬁcant progresses in stem cell biology have generated con-
siderable enthusiasm for the use of these cells in therapeutic
strategies for CNS disorders. Numerous studies have challenged
the common knowledge that the CNS was an immunologically
privileged tissue deprived of any immune reaction and that
transplanted NSPCs were only efﬁcient through mechanisms of
neuronal replacement. It is now clear that neuroprotection and
immunomodulation capacities of these cells play a major part in
the beneﬁcial effects observed in pre-clinical models of neurode-
generative diseases and other CNS affections. Elucidation of these
mechanisms may be a crucial step in the control and improve-
ment of NSPC transplantation as a major therapeutic strategy in
regenerative medicine.
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